Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
Author:
Open Access
- 1 February 2024
- journal article
- review article
- Published by Springer Nature in Oncology and Therapy
- Vol. 12 (1) , 57-72
Abstract
Recent advances have included insights into the clinical value of genomic abnormalities in acute myeloid leukemia (AML) and consequently the development of numerous targeted therapeutic agents that have improved clinical outcome. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. Among them, menin inhibitors could represent a novel group of targeted therapies in AML driven by rearrangement of the lysine methyltransferase 2A (KMT2A) gene, previously known as mixed-lineage leukemia (MLL), or by mutation of the nucleophosmin 1 (NPM1) gene. Recent phase 1/2 clinical trials confirmed the efficacy of SNDX-5613 (revumenib) and KO-539 (ziftomenib) and their acceptable tolerability. Several small molecule menin inhibitors are currently being evaluated as a combination therapy with standard of care treatments. The current paper reviews the recent progress in exploring the inhibitors of menin–KMT2A interactions and their application prospects in the treatment of acute leukemias.Keywords
This publication has 59 references indexed in Scilit:
- The same pocket in menin binds both MLL and JUND but has opposite effects on transcriptionNature, 2012
- Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemiaNature Chemical Biology, 2012
- Crystal Structure of Menin Reveals Binding Site for Mixed Lineage Leukemia (MLL) ProteinJournal of Biological Chemistry, 2011
- New insights to the MLL recombinome of acute leukemiasLeukemia, 2009
- MLL translocations, histone modifications and leukaemia stem-cell developmentNature Reviews Cancer, 2007
- Interaction of MLL Amino Terminal Sequences with Menin Is Required for TransformationCancer Research, 2007
- Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expressionOncogene, 2006
- The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated LeukemogenesisCell, 2005
- Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormalityOncogene, 2001
- Altered Hox expression and segmental identity in Mll-mutant miceNature, 1995